Application Detail
Description of Medical Service
Testing of tumour material in patients with non-small cell lung cancer (NSCLC) to detect mesenchymal-epithelial transition Exon 14 (METex14) skipping alterations, to determine eligibility for treatment with TEPMETKOŽ (tepotinib) through the Pharmaceutical Benefits Scheme (PBS). PBS subsidy is also being sought for tepotinib for the treatment of patients with advanced NSCLC and confirmed METex14 skipping alterations.Description of Medical Condition
NSCLC comprises approximately 85%-90% of all lung cancer. Surgical resection is unfeasible for patients that present with advanced disease. For the selection of therapies for advanced NSCLC, current clinical guidelines recommend performing molecular testing prior to the initiation of an anticancer drug. If a predictive oncogenic marker is identified, treatment with respective approved targeted agents is to be applied when possible. The MET receptor plays an important role in embryogenesis, tumour growth and metastasis. Genetic mutations that affect the splice sites of METex14 were identified predominantly in NSCLC. The consequence of METex14 mutations is the expression of a truncated MET receptor with increased and sustained activation and impaired ubiquitin-mediated degradation, resulting in oncogenic activation of MET. METex14 skipping alterations are reported to occur approximately in 3-5% of NSCLC casesReason for Application
New MBS itemMedical Service Type
TherapeuticPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1145 KB)Application Form (Word 242 KB)
Consultation Survey
Consultation Survey (PDF 560 KB)Consultation Survey (Word 71 KB)
PICO Confirmation
PICO Confirmation (PDF 1313 KB)PICO Confirmation (Word 271 KB)
Assessment Report
-Public Summary Document
Public Summary Document (PDF 650 KB)Public Summary Document (Word 266 KB)